02 new onset autoimmune disorders, primarily psoriasis, in anti-tnf biologic exposed pediatric patients – the develop experience
DEVELOP is a multicenter, prospective, observational registry of the long-term safety and clinical outcomes of 6070 pediatric patients with inflammatory bowel disease (IBD; Crohn ’s disease, ulcerative colitis, or indeterminate colitis) treated with anti-tumor necrosis factor biologics (aTNF) and/or other medical therapies for IBD as part of routine clinical care. DEVELOP has sites in the United States, Canada and the European Union (EU). Our aim was to characterize the in cidence of new autoimmune disorders in a pediatric IBD population exposed to aTNF compared to a population exposed only to non-biologics.
Source: Gastroenterology - Category: Gastroenterology Authors: Richard Colletti, Anne Griffiths, Gigi Veereman, Johanna Escher, James Izanec, Christopher Busse, Yanli Wang, Benjamin Gold Tags: Disease Complications Source Type: research
More News: Autoimmune Disease | Canada Health | Crohn's Disease | Gastroenterology | Inflammatory Bowel Disease | Pediatrics | Psoriasis | Ulcerative Colitis | USA Health